Actively Recruiting
Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
Led by West China Hospital · Updated on 2026-04-13
6
Participants Needed
2
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.
CONDITIONS
Official Title
Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 18 to 70 years old
- Histopathologically confirmed refractory advanced recurrent or metastatic malignant solid tumors unresponsive to second-line treatment
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1
- Expected survival time of at least 3 months
- At least 28 days since last chemotherapy, radiotherapy, or surgery
- At least 6 weeks since last use of nitrosoureas or mitomycin C
- Main organ functions in good condition
- Signed written informed consent form
You will not qualify if you...
- Participation in other drug clinical trials within the last 4 weeks
- Tumor located near major blood vessels or the trachea
- Uncontrolled cardiac symptoms or diseases such as NYHA class II or above heart failure, unstable angina, recent myocardial infarction, or significant arrhythmias requiring treatment
- Pregnant or lactating women
- Active tuberculosis, bacterial or fungal infections grade 2 or higher
- Active HIV, HBV, or HCV infection
- History of psychotropic drug abuse or untreated mental disorders
- Active autoimmune diseases or history of autoimmune diseases (except vitiligo or fully resolved childhood asthma without current treatment)
- Currently receiving immunosuppressive treatment
- History of drug abuse or significant medical, psychological, or social issues
- Known allergy or intolerance to IL-22BP or its components
- Pregnancy plans for female participants or partners of male participants during the study and 12 months after
- Other serious diseases that endanger safety or study completion as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Radiation Oncology
Chengdu, Sichuan, China, 610000
Actively Recruiting
2
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610000
Actively Recruiting
Research Team
X
Xingchen Peng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here